For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 619,693 | 651,784 | ||
| General and administrative expenses | 1,224,546 | 2,012,120 | ||
| Total operating expenses | 1,844,239 | 2,663,904 | ||
| Loss from operations | -1,844,239 | -2,663,904 | ||
| Change in fair value of warrant liability | -12,859 | -9,518 | ||
| Interest income | 56,426 | 15,247 | ||
| Interest expense | 6,301 | 23,054 | ||
| Total other income (expense) | 62,984 | 1,711 | ||
| Net loss | -1,781,255 | -2,662,193 | ||
| Basic EPS | -0.14 | -0.26 | ||
| Diluted EPS | -0.14 | -0.26 | ||
| Basic Average Shares | 12,575,983 | 10,369,127 | ||
| Diluted Average Shares | 12,575,983 | 10,369,127 | ||
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)